EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy

Seren Sevim-Wunderlich iD, Tu Dang, Jana Rossius, Frank Schnütgen iD, Ralf Kühn iD

Genes · 2024

DOI: 10.3390/genes15060706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Seren Sevim-Wunderlich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Genetic Therapy, CRISPR-Cas Systems, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic granulomatous disease (CGD) is an inherited immunodeficiency disease mainly caused by mutations in the X-linked CYBB gene that abrogate reactive oxygen species (ROS) production in phagocytes and microbial defense. Gene repair using the CRISPR/Cas9 system in hematopoietic stem and progenitor cells (HSPCs) is a promising technology for therapy for CGD. To support the establishment of efficient and safe gene therapies for CGD, we generated a mouse model harboring a patient-derived mutation in the CYBB gene. Our CybbC517del mouse line shows the hallmarks of CGD and provides a source for Cybb-deficient HSPCs that can be used to evaluate gene-therapy approaches in vitro and in vivo. In a setup using Cas9 RNPs and an AAV repair vector in HSPCs, we show that the mutation can be repaired in 19% of treated cells and that treatment restores ROS production by macrophages. In conclusion, our CybbC517del mouse line provides a new platform for refining and evaluating novel gene therapies and studying X-CGD pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatous Disease, ChronicGenetic TherapyCRISPR-Cas SystemsDisease Models, AnimalNADPH Oxidase 2AnimalsMiceReactive Oxygen SpeciesHematopoietic Stem CellsHumansMacrophagesMutation

Stichwörter der Autor:innen

CRISPR/Cas9X-CGDgene therapymouse disease model

Substanzen

NADPH Oxidase 2Reactive Oxygen SpeciesCybb protein, mouse

Autor:innen und Institutionen

  • Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
  • Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.
  • German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Frankfurt Cancer Institute, Goethe-University Frankfurt, 60596 Frankfurt am Main, Germany.

ORCID-Profile: Seren Sevim-Wunderlich, Frank Schnütgen, Ralf Kühn

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Sevim-Wunderlich, S., Dang, T., Rossius, J., Schnütgen, F., & Kühn, R. (2024). A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy. Genes. https://doi.org/10.3390/genes15060706

Vancouver

Sevim-Wunderlich S, Dang T, Rossius J, Schnütgen F, Kühn R. A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy. Genes. 2024. doi:10.3390/genes15060706

BibTeX
@article{SevimWunderlich2024,
  author = {Sevim-Wunderlich, Seren and Dang, Tu and Rossius, Jana and Schnütgen, Frank and Kühn, Ralf},
  title = {A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15060706}
}
Kostenlos starten →